Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Isleworth Healthcare Acquisition Corp (ISLE)

Isleworth Healthcare Acquisition Corp (ISLE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Isleworth Healthcare Acquisition Corp. Announces Cancellation of Special Meeting of Shareholders, Redemption of Public Shares and Subsequent Dissolution PR Newswire - Thu Aug 25, 2022

/PRNewswire/ -- Isleworth Healthcare Acquisition Corp. (the "Company") (Nasdaq: ISLE; ISLEW) today announced that it has cancelled its special meeting of...

ISLE : 10.01 (-1.28%)
ISLEWORTH AND CYTOVIA TERMINATE MERGER AGREEMENT PR Newswire - Thu Jun 30, 2022

/PRNewswire/ -- Isleworth Healthcare Acquisition Corporation (Nasdaq: ISLE)("Isleworth"), a special purpose acquisition company, today announced that it has...

ISLE : 10.01 (-1.28%)
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics Globe Newswire - Wed Apr 27, 2022

Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cellsCytovia and Isleworth Healthcare Acquisition...

CLLS : 2.54 (-0.94%)
ISLE : 10.01 (-1.28%)

Barchart Exclusives

Down 39% YTD, Is It Too Early to Buy the Dip in Intel Stock? Barchart - 9 minutes ago
Intel is down 39% this year, and just released disappointing 1Q results. Here is what analysts think of the stock, and whether the worst is over yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot